Mesenchymal stem cells and immunomodulation: Toward new immunosuppressive strategies for the treatment of autoimmune diseases?;Cellules souches mésenchymateuses et immunomodulation : vers de nouvelles stratégies immunosuppressives pour le traitement des maladies auto-immunes ?

Revue de Medecine Interne

Volumn 30, Issue 3, 2009, Pages 287-299

  Larghero, J ^a   Vija, L ^a   Lecourt, S ^a   Michel, L ^a   Verrecchia, F ^a   Farge, D ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Autoimmune diseases; Cell therapy; Immunosuppression; Mesenchymal stem cells

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE DISEASE; BONE DEVELOPMENT; GRAFT VERSUS HOST REACTION; HEART FUNCTION; HEART INFARCTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOGENESIS IMPERFECTA; SHORT SURVEY;

ADULT; ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; CHILD; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED NOD; MULTIPLE SCLEROSIS; MYOCARDIAL INFARCTION; OSTEOGENESIS IMPERFECTA; PAPIO; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TISSUE THERAPY;

EID: 60549092297     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.08.019     Document Type: Short Survey

References (98)

1. Friedenstein A.J., Gorskaja J.F., and Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 4 (1976) 267-274
2. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
3. Caplan A.I. Mesenchymal stem cells. J Orthop Res 9 (1991) 641-650
4. Yin T., and Li L. The stem cell niches in bone. J Clin Invest 116 (2006) 1195-1201
5. Vosshenrich C.A., Cumano A., Muller W., Di Santo J.P., and Vieira P. Pre-B cell receptor expression is necessary for thymic stromal lymphopoietin responsiveness in the bone marrow but not in the liver environment. Proc Natl Acad Sci USA 101 (2004) 11070-11075
6. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
7. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107 (2006) 367-372
8. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., and Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006) 74-85
9. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105 (2005) 4120-4126
10. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
11. Dezawa M., Kanno H., Hoshino M., Cho H., Matsumoto N., Itokazu Y., et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 113 (2004) 1701-1710
12. Sanchez-Ramos J., Song S., Cardozo-Pelaez F., Hazzi C., Stedeford T., Willing A., et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 164 (2000) 247-256
13. Schwartz R.E., Reyes M., Koodie L., Jiang Y., Blackstad M., Lund T., et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 109 (2002) 1291-1302
14. Makino S., Fukuda K., Miyoshi S., Konishi F., Kodama H., Pan J., et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103 (1999) 697-705
15. Oh S.H., Muzzonigro T.M., Bae S.H., LaPlante J.M., Hatch H.M., and Petersen B.E. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. Lab Invest 84 (2004) 607-617
16. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002) 41-49
17. D'Ippolito G., Diabira S., Howard G.A., Menei P., Roos B.A., and Schiller P.C. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 117 (2004) 2971-2981
18. Kucia M., Reca R., Campbell F.R., Zuba-Surma E., Majka M., Ratajczak J., et al. A population of very small embryonic-like (VSEL) CXCR4 + SSEA-1 + Oct-4+ stem cells identified in adult bone marrow. Leukemia 20 (2006) 857-869
19. Simmons P.J., and Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody STRO-1. Blood 78 (1991) 55-62
20. Quirici N., Soligo D., Bossolasco P., Servida F., Lumini C., and Deliliers G.L. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 30 (2002) 783-791
21. Delorme B., Ringe J., Gallay N., Le Vern Y., Kerboeuf D., Jorgensen C., et al. Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood 111 (2008) 2631-2635
22. Gang E.J., Bosnakovski D., Figueiredo C.A., Visser J.W., and Perlingeiro R.C. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 109 (2007) 1743-1751
23. Rider D.A., Nalathamby T., Nurcombe V., and Cool S.M. Selection using the alpha-1 integrin (CD49a) enhances the multipotentiality of the mesenchymal stem cell population from heterogeneous bone marrow stromal cells. J Mol Histol 38 (2007) 449-458
24. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5 (2003) 485-489
25. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
26. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30 (2002) 42-48
27. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
28. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24 (2006) 386-398
29. Groh M.E., Maitra B., Szekely E., and Koc O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 33 (2005) 928-934
30. Nasef A., Chapel A., Mazurier C., Bouchet S., Lopez M., Mathieu N., et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 13 (2007) 217-226
31. Nasef A., Mathieu N., Chapel A., Frick J., François S., Mazurier C., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84 (2007) 231-237
32. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
33. Gieseke F., Schütt B., Viebahn S., Koscielniak E., Friedrich W., Handgretinger R., et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 110 (2007) 2197-2200
34. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106 (2005) 1755-1761
35. Glennie S., Soeiro I., Dyson P.J., Lam E., and Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105 (2005) 2821-2827
36. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102 (2003) 3837-3844
37. Maccario R., Podesta M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90 (2005) 516-525
38. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
39. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2 (2008) 141-150
40. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35 (2005) 1482-1490
41. Deng W., Han Q., Liao L., You S., Deng H., and Zhao R.C. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 24 (2005) 458-463
42. Rasmusson I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76 (2003) 1208-1213
43. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M., and Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006) 1484-1490
44. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105 (2005) 2214-2219
45. Zhang W., Ge W., Li C., You S., Liao L., Han Q., et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13 (2004) 263-271
46. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., and Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177 (2006) 2080-2087
47. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25 (2007) 2025-2032
48. Ramasamy R., Fazekasova H., Lam E.W., Soeiro I., Lombardi G., and Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83 (2007) 71-76
49. Gurevitch O., Prigozhina T.B., Pugatsch T., and Slavin S. Transplantation of allogeneic or xenogeneic bone marrow within the donor stromal microenvironment. Transplantation 68 (1999) 1362-1368
50. Bingaman A.W., Waitze S.Y., Alexander D.Z., Cho H.R., Lin A., Tucker-Burden C., et al. Transplantation of the bone marrow microenvironment leads to hematopoietic chimerism without cytoreductive conditioning. Transplantation 69 (2000) 2491-2496
51. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., and Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108 (2006) 2114-2120
52. Yañez R., Lamana M.L., García-Castro J., Colmenero I., Ramírez M., and Bueren J.A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 24 (2006) 2582-2591
53. Sudres M., Norol F., Trenado A., Grégoire S., Charlotte F., Levacher B., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 176 (2006) 7761-7767
54. Anklesaria P., Kase K., Glowacki J., Holland C.A., Sakakeeny M.A., Wright J.A., et al. Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. Proc Natl Acad Sci USA 84 (1987) 7681-7685
55. Almeida-Porada G., Porada C.D., Tran N., and Zanjani E.D. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 95 (2000) 3620-3627
56. Devine S.M., Bartholomew A.M., Mahmud N., Nelson M., Patil S., Hardy W., et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 29 (2001) 244-255
57. Chapel A., Bertho J.M., Bensidhoum M., Fouillard L., Young R.G., Frick J., et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 5 (2003) 1028-1038
58. Bensidhoum M., Chapel A., Francois S., Demarquay C., Mazurier C., Fouillard L., et al. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 103 (2004) 3313-3319
59. Uccelli A., Pistoia V., and Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol 28 (2007) 219-226
60. Djouad F., Fritz V., Apparailly F., Louis-Plence P., Bony C., Sany J., et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 52 (2005) 1595-1603
61. Augello A., Tasso R., Negrini S.M., Cancedda R., and Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56 (2007) 1175-1186
62. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 61 (2007) 219-227
63. Kushida T., Inaba M., Hisha H., Ichioka N., Esumi T., Ogawa R., et al. Crucial role of donor-derived stromal cells in successful treatment for intractable autoimmune diseases in MRL/LPR mice by BMT via portal vein. Stem Cells 19 (2001) 226-235
64. Lee R.H., Seo M.J., Reger R.L., Spees J.L., Pulin A.A., Olson S.D., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 103 (2006) 17438-17443
65. Papadaki H.A., Boumpas D.T., Gibson F.M., Jayne D.R., Axford J.S., Gordon-Smith E.C., et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 115 (2001) 167-174
66. Papadaki H.A., Kritikos H.D., Gemetzi C., Koutala H., Marsh J.C., Boumpas D.T., et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 99 (2002) 1610-1619
67. Papadaki H.A., Tsagournisakis M., Mastorodemos V., Pontikoglou C., Damianaki A., Pyrovolaki K., et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant 36 (2005) 1053-1063
68. Del Papa N., Quirici N., Soligo D., Scavullo C., Cortiana M., Borsotti C., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54 (2006) 2605-2615
69. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56 (2007) 1994-2004
70. Larghero J., Farge D., Braccini A., Lecourt S., Scherberich A., Foïs E., et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from systemic sclerosis patients. Ann Rheum Dis 67 (2008) 443-449
71. Bocelli-Tyndall C., Bracci L., Spagnoli G., Braccini A., Bouchenaki M., Ceredig R., et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 46 (2007) 403-408
72. Dazzi F., van Laar J.M., Cope A., and Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res Ther 9 (2007) 206
73. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., and Caplan A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 16 (1995) 557-564
74. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S., Caplan A.I., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18 (2000) 307-316
75. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11 (2005) 389-398
76. Frassoni F., Labopin M., Bacigalupo A., Gluckman E., Rocha V., Bruno B., et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hemopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched pair analysis (abstract). Bone Marrow Transplant 29 (2002) 75
77. Ball L.M., Bernardo M.E., Roelofs H., Lankester A., Cometa A., Egeler R.M., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110 (2007) 2764-2767
78. Fouillard L., Chapel A., Bories D., Bouchet S., Costa J.M., Rouard H., et al. Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. Leukemia 21 (2007) 568-570
79. Fouillard L., Bensidhoum M., Bories D., Bonte H., Lopez M., Moseley A.M., et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 17 (2003) 474-476
80. Ikehara S. A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases. J Autoimmun 30 (2008) 108-115
81. Ringdén O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lönnies H., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
82. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
83. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1269-1274
84. Ning H., Yang F., Jiang M., Hu L., Feng K., Zhang J., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22 (2008) 593-599
85. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5 (1999) 309-313
86. Horwitz E.M., Gordon P.L., Koo W.K.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99 (2002) 8932-8937
87. Quarto R., Mastrogiacomo M., Cancedda R., Kutepov S.M., Mukhachev V., Lavroukov A., et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 344 (2001) 385-386
88. Koc O.N., Day J., Nieder M., Gerson S.L., Lazarus H.M., and Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 30 (2002) 215-222
89. Christopeit M., Schendel M., Föll J., Müller L.P., Keysser G., and Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 22 (2008) 1062-1064
90. Chan J.L., Tang K.C., Patel A.P., Bonilla L.M., Pierobon N., Ponzio N.M., et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107 (2006) 4817-4824
91. Stagg J., Pommey S., Eliopoulos N., and Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 107 (2006) 2570-2577
92. Eliopoulos N., Stagg J., Lejeune L., Pommey S., and Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106 (2005) 4057-4065
93. Devine S.M., Cobbs C., Jennings M., Bartholomew A., and Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101 (2003) 2999-3001
94. François S., Bensidhoum M., Mouiseddine M., Mazurier C., Allenet B., Semont A., et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 24 (2006) 1020-1029
95. Wang Y., Huso D.L., Harrington J., Kellner J., Jeong D.K., Turney J., et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 7 (2005) 509-519
96. Miura M., Miura Y., Padilla-Nash H.M., Molinolo A.A., Fu B., Patel V., et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24 (2006) 1095-1103
97. Tolar J., Nauta A.J., Osborn M.J., Panoskaltsis Mortari A., McElmurry R.T., Bell S., et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25 (2007) 371-379
98. Rubio D., Garcia-Castro J., Martín M.C., de la Fuente R., Cigudosa J.C., Lloyd A.C., et al. Spontaneous human adult stem cell transformation. Cancer Res 65 (2005) 3035-3039